Completed PHASE2 INTERVENTIONAL NCT00044148

The Effect of LY333531 on Protein in the Urine in Patients With Type 2 Diabetes

The Effect of LY333531 on Albuminuria in Patients With Type 2 Diabetes A Pilot Clinical Trial

Sponsor: Chromaderm, Inc.

Interventions LY333531

Updated 6 times since 2017 Last updated: Jan 30, 2017 Started: Jul 16, 2002 Primary completion: Apr 28, 2004 Completion: Apr 28, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Diabetic Nephropathy and is currently completed. Chromaderm, Inc. leads this study, which shows 6 recorded versions since 2002 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jul 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chromaderm, Inc.

Data source: Chromaderm, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Baltimore, United States , Chicago, United States , Dallas, United States , Greenville, United States , Jacksonville, United States , La Jolla, United States , Lexington, United States , Minneapolis, United States , New York, United States and 5 more locations